Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.

Pehlivanidis A, Spyropoulou AC, Tourkantonis A, Papadimitriou GN.

Clin Neuropharmacol. 2010 May;33(3):168. doi: 10.1097/WNF.0b013e3181dc4e3d. No abstract available.

PMID:
20502137
2.

Amisulpride treatment for clozapine-induced sialorrhea.

Praharaj SK, Sarkar S, Sinha VK.

J Clin Psychopharmacol. 2009 Apr;29(2):189-90. doi: 10.1097/JCP.0b013e318199f264. No abstract available.

PMID:
19512987
3.
4.

Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.

Stone JM, Bressan RA, Erlandsson K, Ell PJ, Pilowsky LS.

Psychopharmacology (Berl). 2005 Aug;180(4):664-9. Epub 2005 Sep 14.

PMID:
15719226
5.

Sulpiride and refractory panic disorder.

Nunes EA, Freire RC, Dos Reis M, de Oliveira E Silva AC, Machado S, Crippa JA, Dursun SM, Baker GB, Hallak JE, Nardi AE.

Psychopharmacology (Berl). 2012 Sep;223(2):247-9. doi: 10.1007/s00213-012-2818-6. Epub 2012 Aug 5. No abstract available.

PMID:
22864966
6.

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.

Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Mazière B, Paillère-Martinot ML.

J Clin Psychopharmacol. 2001 Apr;21(2):207-14.

PMID:
11270918
7.

The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.

Kim SW, Shin IS, Kim JM, Youn T, Yang SJ, Hwang MY, Yoon JS.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):224-6. doi: 10.1097/WNF.0b013e318184fafd.

PMID:
19644229
8.

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.

J Pharmacol Exp Ther. 1997 Jan;280(1):83-97.

9.

Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.

Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn KU.

Biol Psychiatry. 2006 Mar 15;59(6):536-45. Epub 2005 Sep 1.

PMID:
16139819
11.
12.

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O.

Psychopharmacology (Berl). 1998 Jun;137(3):223-32.

PMID:
9682999
13.

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Agai Csongor E, Domány G, Kiss B, Szombathelyi Z.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):529-39. doi: 10.1007/s00210-008-0311-x. Epub 2008 Jun 12.

PMID:
18548231
14.

Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.

Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS.

Psychopharmacology (Berl). 2004 Sep;175(3):367-73.

PMID:
14997280
15.

Switching to amisulpride monotherapy for treatment-resistant schizophrenia.

Kontaxakis VP, Havaki-Kontaxaki BJ, Ferentinos PP, Paplos KG, Soldatos CR.

Eur Psychiatry. 2006 Apr;21(3):214-7. Epub 2006 Mar 13.

PMID:
16531015
16.
17.

Amisulpride: from animal pharmacology to therapeutic action.

Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S29-36. Review.

PMID:
9218165
18.

Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.

Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C.

Clin Neuropharmacol. 2005 Mar-Apr;28(2):66-71.

PMID:
15795548
19.

Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.

Zink M, Knopf U, Henn FA, Thome J.

Pharmacopsychiatry. 2004 Jan;37(1):26-31. Review.

PMID:
14750045
20.

Dopamine D4 receptors: a new opportunity for research on schizophrenia.

Liégeois J, Eyrolles L, Bruhwyler J, Delarge J.

Curr Med Chem. 1998 Apr;5(2):77-100. Review.

PMID:
9481035
Items per page

Supplemental Content

Write to the Help Desk